Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 21, 2023; 29(43): 5818-5833
Published online Nov 21, 2023. doi: 10.3748/wjg.v29.i43.5818
Published online Nov 21, 2023. doi: 10.3748/wjg.v29.i43.5818
Knowledge | Correct | Wrong | Unclear |
IBD is a group of chronic, non-specific recurrent intestinal inflammatory diseases, including UC and CD | 316 (89.5) | 2 (0.6) | 35 (9.9) |
At present, many factors, such as heredity, immunity, environment, and microorganisms, are involved in the pathogenesis of the disease | 74 (21.0) | 185 (52.4) | 94 (26.6) |
Symptoms of IBD can include abdominal pain, diarrhea, bloody stool, anemia, fever, joint swelling, pain, etc. | 293 (83.0) | 13 (3.7) | 47 (13.3) |
Extraintestinal manifestations of IBD include oral ulcers, joint injury, skin injury, eye lesions, hepatobiliary diseases, etc. | 212 (60.1) | 32 (9.1) | 109 (30.9) |
IBD often occurs in young adults and is more common between the ages of 20-50 yr | 267 (75.6) | 16 (4.5) | 70 (19.8) |
IBD is a lifelong disease, and the patient’s condition is prolonged and repeated. At present, there is no specific and effective medicine or method to cure the disease | 293 (83.0) | 11 (3.1) | 49 (13.9) |
Colonoscopy and mucosal biopsy are the best methods to establish the diagnosis and assess the disease’s severity in patients with IBD | 285 (80.7) | 6 (1.7) | 62 (17.6) |
Generally, medical treatment is the main treatment for IBD, but surgical treatment is needed when intestinal obstruction, intestinal perforation, and canceration occur | 275 (77.9) | 5 (1.4) | 73 (20.7) |
The treatment of patients with IBD varies widely among individuals, with different classifications and severity of the disease leading to different treatment outcomes and efficacy | 299 (84.7) | 1 (0.3) | 53 (15.0) |
Drugs for treating IBD include hormones, aminosalicylic acid drugs, immunosuppressants (azathioprine, methotrexate, etc.), and biological agents | 274 (77.6) | 5 (1.4) | 74 (21.0) |
There are no side effects after treatment with glucocorticoids, etc. | 149 (42.2) | 39 (11.0) | 165 (46.7) |
Currently, the biological agents approved for treating IBD in China include infliximab, vidrizumab, and ustekinumab | 292 (82.7) | 6 (1.7) | 55 (15.6) |
All patients with IBD can’t normally absorb the nutrients they intake | 232 (65.7) | 60 (17.0) | 61 (17.3) |
Emotion, smoking, drinking, and other behaviors will not affect IBD | 286 (81.0) | 36 (10.2) | 31 (8.8) |
- Citation: Shao XX, Fang LY, Guo XR, Wang WZ, Shi RX, Lin DP. Knowledge, attitude, and practice of patients living with inflammatory bowel disease: A cross-sectional study. World J Gastroenterol 2023; 29(43): 5818-5833
- URL: https://www.wjgnet.com/1007-9327/full/v29/i43/5818.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i43.5818